Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coloplast ASCLPBF 77 EV-to-EBITDA is 12.45 as of Jul. 25, 2026, which is 52% below its 10-year median of 25.87. GuruFocus rates CLPBF with a GF Score™ of 77/100 and a GF Value™ of $125.97 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 510 Medical Devices & Instruments companies, Coloplast AS ranks better than 56.86% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Coloplast AS's enterprise value is $17,365 Mil.
Coloplast AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $1,395 Mil. Therefore, Coloplast AS's EV-to-EBITDA for today is 12.45.
The historical rank and industry rank for Coloplast AS's EV-to-EBITDA or its related term are showing as below:
CLPBF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.12 Med: 25.87 Max: 52.35
Current: 12.75
During the past 13 years, the highest EV-to-EBITDA of Coloplast AS was 52.35. The lowest was 12.12. And the median was 25.87.
CLPBF's EV-to-EBITDA is ranked better than 56.86% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 13.845
vs CLPBF: 12.75
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Coloplast AS (OTCPK:CLPBF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Coloplast AS's PE Ratio (TTM) for today is calculated as:
Coloplast AS's share price for today is $64.00.
Coloplast AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.467.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Coloplast AS's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Coloplast AS's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Coloplast AS's EV-to-EBITDA falls into.
Coloplast AS's current Enterprise Value is $17,365 Mil.
Coloplast AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,395 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coloplast AS (CLPBF) has a EV-to-EBITDA of 12.45 as of Jul. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Coloplast AS. This is 52% below median its historical median of 25.87. Over the past decade, Coloplast AS's EV-to-EBITDA has ranged from 12.12 to 52.35. According to the industry distribution chart, Coloplast AS ranks #220 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 43.1%.
Is Coloplast AS's EV-to-EBITDA too high?
Coloplast AS's current EV-to-EBITDA of 12.45 is 52% below median its 10-year median of 25.87. Over the past 10 years, this metric has ranged from a low of 12.12 to a high of 52.35. The Medical Devices & Instruments industry median EV-to-EBITDA is 13.85. Coloplast AS's value of 12.45 is 10.1% below this industry median. Based on the distribution chart, Coloplast AS ranks #220 out of 510 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Coloplast AS has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coloplast AS ranks #220 out of 510 companies for EV-to-EBITDA. This puts Coloplast AS in the upper half of its industry. The industry median EV-to-EBITDA is 13.85. Coloplast AS's value of 12.45 is 10.1% below this benchmark. Historically, Coloplast AS's own EV-to-EBITDA has ranged from 12.12 to 52.35 over the past decade. While the company's 10-year median is 25.87 vs. the industry median of 13.85, Coloplast AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.85, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coloplast AS's current EV-to-EBITDA of 12.45 is 10.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Coloplast AS. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coloplast AS's current EV-to-EBITDA is 12.45, which is 52% below median its own 10-year median of 25.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $125.97, compared to a current price of $64.00 — trading 49.2% below its estimated fair value. The current EV-to-EBITDA is 12.45, which is 52% below median its 10-year median of 25.87 and 10.1% below the Medical Devices & Instruments industry median of 13.85. Coloplast AS's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Coloplast AS (CLPBF), the current EV-to-EBITDA is 12.45 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBF) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $64.00 is trading 49.2% below its estimated GF Value™ of $125.97.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBF:
EV-to-EBITDA: 12.45 (52% below median its 10-year median of 25.87)
GF Value™: $125.97 vs. price of $64.00 (49.2% below fair value)
Industry Position: 10.1% below the Medical Devices & Instruments median (#220 of 510)
No single metric tells the full story. See the CLPBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
77GF Score
Get the complete analysis for CLPBF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBF has been successfully added to your 
